Auro Laboratories
AUROLABBSE

Auro Laboratories

₹267.706.50 (2.49%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
255.00
Today’s high
269.95
52 week low
159.00
52 week high
317.00
Open price
269.95
Previous close
261.20
Live volume
1,239
Lower circuit
248.15
Upper circuit
274.25

Fundamentals

Market Cap
₹163Cr
ROE
2.42%
P/E Ratio(TTM)
55.11
EPS(TTM)
4.74
P/B Ratio
3.74
Dividend Yield
0.00%
Industry P/E
42.82
Book Value
69.92
Debt to Equity
1.01
Face Value
10

Financial performance

Quarterly
Yearly
All Financials
DEC '25
Revenue (Cr)
₹9.57
-2.55%
Profit (Cr)
₹1.95
+170.83%
-5-1.2503.757.5
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Revenue growthValue
1Y (TTM)+200%
3Y CAGR-27%
Profit growthValue
1Y (TTM)+3,800%
3Y CAGR-14%

About

Auro Laboratories Limited is a pharmaceutical company that commenced manufacturing activities of Active Pharmaceutical Ingredients (APIs) back in 1992. The company's governance philosophy includes core values of independence, integrity, accountability, and fairness in all its business transactions. It is also committed to enhancing shareholder value in a fair and transparent manner by benchmarking itself against the best global business practices. A key specialty is Metformin Hydrochloride, an oral drug used for managing type 2-diabetes, which the company manufactures as an API. With existing registrations and regulatory approvals, the company has an established customer base in India and various foreign countries for growth. To meet future demand, the company is doubling its Metformin HCL production from 1800 to 3600 metric tons per annum.;
CEO/MD
Mr. Sharat Deorah
Founded in
1989
BSE symbol
530233

Shareholding Pattern

Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Promoters
52.18%
Retail And Others
47.82%
Mutual Funds
0.01%
2026
5
Feb
Quarterly Result
Release date
2025
12
Nov
Quarterly Result
Release date
14
Aug
Quarterly Result
Release date
Events calendar
View upcoming events in other stocks